Research programme: alkylatlng histone deacetylase inhibitors - Mundipharma EDO
Latest Information Update: 10 Jun 2015
At a glance
- Originator Northlake International
- Developer Mundipharma EDO
- Class Antineoplastics; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 27 Nov 2012 Early research Haematological malignancies in United Kingdom (unspecified route)